Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Chicago, Illinois
- Most recent report
- 10-Q, filed Aug 10, 2026
- Incorporated
- Delaware
- Filings on record
- 490 filings
- On EDGAR
- CIK 1878313
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
Financials 8 of 18
News 8 of 109
Prospectuses and Registrations 8 of 41
- S-3 Shelf registration statement Aug 21, 2026
- 424B5 Prospectus supplement for an offering May 14, 2026
- S-8 Registration statement for an employee plan Apr 7, 2026
- 424B5 Prospectus supplement for an offering Mar 4, 2026
- 424B5 Prospectus supplement for an offering Mar 2, 2026
- S-8 Registration statement for an employee plan Mar 28, 2025
- 424B5 Prospectus supplement for an offering Mar 26, 2025
- 424B5 Prospectus supplement for an offering Dec 23, 2024
Proxies 8 of 9
- DEFA14A Extra proxy material May 19, 2026
- DEFA14A Extra proxy material Apr 27, 2026
- DEFA14A Extra proxy material Apr 7, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 7, 2026
- DEFA14A Extra proxy material Apr 8, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 8, 2025
- PRE 14A Preliminary proxy statement Mar 28, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 16, 2024
Ownership 8 of 253
- 4 Insider reported a trade Sep 1, 2026
- 4 Insider reported a trade Aug 26, 2026
- 4 Insider reported a trade Aug 24, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- 4 Insider reported a trade Jul 2, 2026
- 4 Insider reported a trade Jul 2, 2026
- 4 Insider reported a trade Jul 2, 2026
- 4 Insider reported a trade Jul 2, 2026
Other 8 of 60
Everything here comes from MAIA Biotechnology, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.